Minnesota Senate Bill SF1106

Minnesota 2025-2026 Regular Session

• Introduced: 2/6/25
• Refer: 2/6/25

Caption

Dispensing fee requirements on health plan companies providing prescription coverage provision

Summary

SF 1106 would require health plan companies that offer prescription drug coverage to pay pharmacies a dispensing fee that is at least as high as the fee paid under Minnesota’s Medical Assistance pharmacy reimbursement statute. In practical terms, the bill ties the minimum dispensing fee for private health plans to the state Medicaid dispensing fee standard, creating a floor for pharmacy reimbursement when a covered prescription is filled. The bill expressly excludes managed care plans and county-based purchasing plans when they are covering enrollees in public health care programs under chapters 256B and 256L, so it does not change the reimbursement rules for Medical Assistance or MinnesotaCare coverage. The proposal would add a new section to Minnesota Statutes chapter 62Q, which governs health plan regulation, and would affect health insurers and pharmacy providers in the commercial market.

Impact

If enacted, the bill would amend Minnesota’s health insurance laws by adding a new requirement in chapter 62Q for commercial health plans with prescription coverage to pay a minimum pharmacy dispensing fee. It would not alter the existing dispensing fee structure for public program coverage under Medical Assistance or MinnesotaCare, because those plans are specifically excluded. The main affected parties would be private health plan companies and pharmacies, with the bill likely increasing reimbursement obligations for insurers and potentially improving pharmacy compensation for dispensing prescriptions.

Sentiment

The available record shows limited formal debate, but the bill’s structure suggests a pro-pharmacy, pro-reimbursement policy approach. Because there are no committee transcripts or recorded votes in the provided materials, there is no documented opposition or support beyond the bill’s introduction and referral. The absence of recorded controversy indicates that, at least in the available history, the measure had not yet generated a visible public or legislative split.

Contention

The main point of potential contention is the cost impact on health plan companies, which would be required to pay a dispensing fee no lower than the Medicaid benchmark for commercial prescription coverage. Supporters would likely include pharmacies and pharmacy advocates, who may view the bill as a way to ensure fair reimbursement and help offset dispensing costs. Any opposition would likely come from insurers or employer-sponsored plan interests concerned about higher premiums or increased claims costs. The explicit exclusion of Medical Assistance and MinnesotaCare may also be notable, as it limits the bill’s reach to private coverage and avoids changing public program reimbursement rules.